🧬 BioMed Pulse · 2026-11-12 02:01 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses, and New Cures

Thursday, 12 November 2026 — 02:00 UTC

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the DRC has now spread to Kenya and Nigeria, with WHO reporting sustained high-level transmission across 61-plus health zones and a cumulative death toll exceeding 800; it is officially the largest Ebola outbreak ever recorded in the DRC. [1] [2] [3]

Mood: Elevated concern — a historic hemorrhagic fever crisis runs alongside a never-before-seen human virus in France and an approaching European respiratory season.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (EBOLA) — DRC, KENYA, NIGERIA

  • As of 6 November 2026, the Bundibugyo virus disease (BVD) outbreak in the DRC remains at sustained high-level transmission with continued geographic spread across six provinces: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo. [1] [3]
  • An imported BVD case was confirmed in Kenya on 5 October 2026 in a patient who traveled from DRC through Uganda; Nigeria has also reported imported cases, bringing the outbreak to three countries. [4] [2]
  • Since the previous WHO Disease Outbreak News on 23 October, the DRC outbreak has expanded further geographically, though some areas have shown a slight decline in new cases. [1]
  • As of 15 July 2026 — the last full case count published by WHO — a cumulative 2,124 confirmed cases and 828 deaths had been recorded in the DRC alone, a case-fatality ratio of roughly 39 percent. [5]
  • ECDC assessed importation risk to Europe as low but deployed experts to Nigeria to support investigations and local response following confirmed cases in that country. [6] [7]
  • CDC mobilized an Ebola response as early as May 2026 and introduced enhanced airport screening at Washington Dulles and Atlanta Hartsfield-Jackson for travelers from affected regions. [8] [9] [10]

SHAMONDA VIRUS — FRANCE (FIRST HUMAN CASE EVER)

  • On 20 October 2026, France notified WHO of the world's first documented human infection with Shamonda virus (SHAV), a Simbu-group orthobunyavirus previously known only to infect animals.
  • The case is an immunocompromised older man from eastern France with no recent travel history; he presented with severe neurological symptoms after the onset of illness.
  • ECDC is actively monitoring the situation, noting SHAV has circulated in European livestock for decades but had never before caused human disease.

RESPIRATORY SEASON — EUROPE

  • ECDC is warning that the cold season is driving rising circulation of influenza, RSV, COVID-19, and pneumococcal disease across EU/EEA countries, increasing pressure on healthcare services.
  • A new ECDC report concludes that universal RSV immunisation of newborns could substantially reduce infant hospitalisations across Europe this season, adding urgency to rollout decisions.
  • A human challenge study enrolling 65-to-75-year-olds (NCT07713628) opened 10 November 2026 to study immune responses to RSV B — timing that underlines the clinical relevance of this virus in older populations.

MERS-COV — SAUDI ARABIA

  • Between 1 January and 5 October 2026, Saudi Arabia reported eight laboratory-confirmed MERS-CoV infections including one death, cases detected across six locations including Riyadh and Tabuk.
  • ECDC's weekly Communicable Disease Threats Reports have tracked MERS-CoV continuously throughout autumn 2026 as an ongoing surveillance concern.

PNEUMONIA OF UNDETERMINED ETIOLOGY — RUSSIA

  • WHO was notified on 2 October 2026 of the death of an employee of the Irkutsk Antiplague Research Institute (APRI) of Siberia and the Far East in Russia following hospitalization for severe pneumonia; the etiology remains undetermined.
  • ECDC included this event in its week-41 and week-42 Communicable Disease Threats Reports under "pneumonia of unknown aetiology," signaling continued monitoring.

YELLOW FEVER — AFRICA AND AMERICAS

  • Between 1 January and 12 October 2026, nine countries in the WHO African Region recorded 67 confirmed yellow fever cases including 18 deaths; affected countries include Burkina Faso, Cameroon, and the Central African Republic.
  • Separately, six countries in the Americas reported 79 human infections from January through 26 May 2026, continuing elevated activity that began rising in 2025.

🧬 LONGEVITY & AGING

GDF11 AND MUSCLE AGING — SARCOPENIA MECHANISM

  • A new study published in Genes and Disease finds that GDF11 — a circulating protein that declines with age — restores the function of skeletal muscle satellite cells (the cells responsible for muscle repair) by activating the MYC transcription factor, thereby ameliorating sarcopenia (age-related muscle loss).
  • The finding points to a GDF11-MYC axis as a potential therapeutic target for the tens of millions of older adults affected by progressive muscle wasting.

STATIN DISCONTINUATION IN OLDER ADULTS — FRAILTY MATTERS

  • A large population-wide retrospective cohort study published in Lancet Healthy Longevity used Clinical Practice Research Datalink data from England and finds that the efficacy and safety of stopping statins in patients aged 65 and older differs significantly according to frailty status.
  • An accompanying editorial by Bardoczi and Rodondi cautions that frailty assessment should be a formal part of deprescribing decisions for statins in older patients before any discontinuation is made.

ANIMAL PROTEIN, COGNITION, AND DEMENTIA SEX DISPARITY

  • A global ecological analysis in Future Science OA (published 2 November 2026) by You et al. links national-level animal protein supply to cognitive aging trajectories and explores whether differences in protein intake help explain the persistent female-male gap in dementia incidence worldwide.

AI FOR BIOLOGICAL AGE FROM FACE PHOTOGRAPHS

  • Haugg, Lee, He and colleagues (Lancet Digital Health) developed FAHR-Face, a foundation AI model that estimates health and biological age from standard face photographs, validated across multiple centres — positioning facial imaging as a potential low-cost longevity biomarker.

AI CARDIAC MRI VERSUS CLINICIANS FOR MORTALITY PREDICTION

  • Joy et al. (Lancet Digital Health) report in a multicentre prognostic study that AI-based left-ventricular segmentation of cardiac MRI matches or outperforms clinician segmentation for predicting all-cause mortality, suggesting AI tools can extend cardiac aging assessments to larger populations.

PLANT-BASED DIETS AND HEALTHY AGING — TAIWAN COHORT

  • An ongoing prospective study (NCT07151365) is enrolling 5,000 Tzu Chi volunteers in Taiwan aged 45 and older to track whether vegetarian and plant-based diets protect against diabetes, stroke, gout, and other aging-related conditions over time.

OLDER ADULTS IN HUMANITARIAN CRISES — LONGEVITY EQUITY

  • A cluster of papers in Lancet Healthy Longevity highlights that older adults are systematically overlooked in humanitarian emergencies, facing gaps in palliative care, nutrition, and sexual and reproductive health services that accelerate biological aging.
  • Authors from multiple institutions propose the PARTICIPATE framework — a rights-based model — to integrate older people's specific health needs into crisis response planning.

💊 NEW CURES & APPROVALS

CONEXXENCE — DENOSUMAB BIOSIMILAR (BONE LOSS)

  • Fresenius Kabi USA LLC received an FDA supplemental approval for CONEXXENCE (denosumab-bnht, BLA761398), a biosimilar to Prolia/Xgeva targeting RANK-L to reduce bone resorption in osteoporosis and cancer-related bone disease — conditions disproportionately affecting older adults.

ZYNLONTA — LONCASTUXIMAB TESIRINE-LPYL (LYMPHOMA)

  • ADC Therapeutics SA received a supplemental FDA approval for ZYNLONTA (loncastuximab tesirine-lpyl, BLA761196), an antibody-drug conjugate targeting CD19-expressing B-cell lymphoma; the update expands the clinical profile of this targeted cancer therapy.

RYBREVANT FASPRO — AMIVANTAMAB SUBCUTANEOUS (LUNG CANCER)

  • Janssen Biotech obtained a supplemental approval for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj, BLA761433), enabling subcutaneous delivery of the EGFR/MET bispecific antibody for NSCLC — reducing infusion burden for patients receiving long-term therapy.

WELIREG — BELZUTIFAN (KIDNEY CANCER / VHL DISEASE)

  • Merck Sharp and Dohme received a supplemental FDA approval for WELIREG (belzutifan, NDA215383), a first-in-class HIF-2 alpha inhibitor used in VHL disease-associated tumors and advanced renal cell carcinoma.

ORGOVYX — RELUGOLIX (PROSTATE CANCER)

  • Sumitomo Pharma America received a supplemental approval for ORGOVYX (relugolix, NDA214621), an oral GnRH receptor antagonist for advanced prostate cancer, which allows androgen-deprivation therapy without injections.

HYMPAVZI — MARSTACIMAB-HNCQ (HEMOPHILIA)

  • Pfizer Inc received a supplemental FDA approval for HYMPAVZI (marstacimab-hncq, BLA761369), a tissue factor pathway inhibitor antibody for hemophilia A and B prophylaxis.

AMJEVITA — ADALIMUMAB BIOSIMILAR (MULTIPLE INDICATIONS)

  • Amgen Inc received a supplemental approval for AMJEVITA (adalimumab-atto, BLA761024), the adalimumab biosimilar covering inflammatory conditions including rheumatoid arthritis, Crohn's disease, and psoriasis.

RELEUKO — FILGRASTIM BIOSIMILAR (NEUTROPENIA)

  • Kashiv BioSciences LLC received a supplemental approval for RELEUKO (filgrastim-ayow, BLA761082), a G-CSF biosimilar used to stimulate white blood cell production after chemotherapy or in severe chronic neutropenia.

🧪 CLINICAL TRIALS

RSV HUMAN CHALLENGE IN OLDER ADULTS — NCT07713628

  • Opened 10 November 2026; a sequential cohort study enrolling 20 healthy non-smoking adults aged 65-75 to characterise immune responses to deliberate RSV B inoculation, with a 6-person sentinel safety cohort proceeding first.
  • The trial directly addresses the immune vulnerability of older adults to RSV, relevant context for ECDC's parallel push for universal infant RSV immunisation.

PSILOCYBIN-ENHANCED COGNITIVE TRAINING IN AGING — NCT07721467

  • An NIH-sponsored study enrolling older adults and Alzheimer's-spectrum patients to test whether a single dose of psilocybin can enhance neuroplasticity and amplify the benefits of structured cognitive training on memory and attention.

PLANT-BASED DIET AND AGING — NCT07151365

  • Prospective cohort of 5,000 Tzu Chi volunteers in Taiwan, middle-aged to older adults, tracking vegetarian diet adherence against incidences of diabetes, stroke, and gout over time.

VACCINE RESPONSES IN AGING AND FRAILTY — NCT05291676

  • Ongoing study comparing immunologic, transcriptomic, and metabolomic response signatures of Fluad versus Fluzone High-Dose influenza vaccines in adults aged 65 and over, to identify biological predictors of vaccine efficacy in frail older individuals.

GENE TRANSFER FOR LATE-ONSET POMPE DISEASE — NCT04174105

  • Phase 1/2 open-label ascending-dose multicenter trial of AT845 (AAV gene therapy targeting acid alpha-glucosidase deficiency) in adults aged 18 and older with late-onset Pompe disease, assessing safety and efficacy in both ambulatory and non-ambulatory patients.

TSLPR-CART CELLS FOR RELAPSED B-ALL — NCT07572136

  • An NIH-sponsored Phase 1 study enrolling patients with recurrent or refractory CRLF2-R/TSLPR-overexpressing B-cell acute lymphoblastic leukemia testing anti-CRLF2-R chimeric antigen receptor T cells — a next-generation CAR-T approach for a mutation that confers treatment resistance.

NEMTABRUTINIB FOR BTK-INHIBITOR-REFRACTORY CLL — NCT07796373

  • An NIH-sponsored study enrolling CLL/SLL patients who have failed both covalent BTK inhibitors (or pirtobrutinib) and a BCL2 inhibitor, testing nemtabrutinib, a non-covalent BTK inhibitor designed to retain activity against resistance mutations.

📢 PUBLIC HEALTH

ECDC EPI-PLUS SURVEILLANCE PLATFORM ROLLOUT

  • ECDC and Italy's Istituto Superiore di Sanita held training this week (week of 11 November 2026) for 40 national epidemiologists in nine pilot countries ahead of the 2027 launch of Epi+, a multilingual event-based surveillance platform designed to detect and assess emerging public health threats earlier.

ECDC PUBLIC HEALTH EMERGENCY PREPAREDNESS ASSESSMENTS

  • The first cycle of EU Public Health Emergency Preparedness Assessments (PHEPAs) has been completed, showing strong commitment to readiness across Europe but persistent common challenges in cross-border response coordination, according to ECDC.

DRUG-RESISTANT BACTERIA — CDC SHARP RISE WARNING

  • A CDC report released 23 September 2025 found a dramatic increase in dangerous drug-resistant bacteria in U.S. healthcare settings, reinforcing the need for antibiotic stewardship as the respiratory season elevates hospital admissions.

CDC TRAVELER BIOSURVEILLANCE MILESTONE

  • CDC's Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants as of January 2026, strengthening the ability to detect emerging pathogen variants arriving on U.S. soil — directly relevant given imported BVD cases now appearing in Kenya and Nigeria.

BIOMED PULSE is an informational briefing only and does not constitute medical advice. Sources: WHO Disease Outbreak News, ECDC News and CDTR, CDC Newsroom, openFDA Drugs@FDA, ClinicalTrials.gov, Europe PMC / PubMed.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  6. Importation of Ebola cases to Kenya and Nigeria: ECDC assesses… — ECDC News
  7. ECDC to deploy experts as Ebola cases emerge in Kenya and Nigeria — ECDC News
  8. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
  9. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  10. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261112-02-v134 · 2026-11-12 02:01 UTC · pulse.uzylab.com